The Genentech Commitment

Couple Hero with Child

The Genentech
Commitment

Couple Hero with Child

A Strong Legacy in Biotechnology

Since 1976, Genentech has been a leader in the field of biotechnology. We discover, develop, manufacture, and commercialize medicines to treat patients with serious and life-threatening medical conditions.

Our Pledge to Progress

With our reinvestments in revenue, we have helped to maintain our innovations and are dedicated to creating more breakthroughs in ophthalmology.

Reinvestment chart icon

CHf=confoederatio helvetica franc.

Doctor talking to patient in waiting room

Success by the Numbers

Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer, the first medicine for primary progressive multiple sclerosis, and the first FDA-approved antibody therapy for various retinal diseases.

42 years icon

medicines on the market addressing advanced, unmet medical needs 

33 FDA granted breakthrough therapy designation drugs

FDA-granted breakthrough therapy designations (BTDs); nearly 20% of all approved BTDs in the US 

"About 13 billion dollars in investments

billion dollars in R&D investment in 2019 (#1 of any pharmaceutical/biotech company)

Since 1985, Genentech has donated more than $3.5 billion in free medicine.

Syringe and Medicine

>2.2 million patients able to access Genentech medicines through Genentech Access Solutions

Connected employees

>25,000 US employees across Genentech and Roche Diagnostics

Orbit Icon

785k square feet of research—one of the largest biologics research facilities in the world 

Going Beyond Drug Development in Ophthalmology

At Genentech, we are committed to innovating beyond the current standards of care to transform how patients experience ophthalmic care. 

Ways we are looking toward the future

  • Utilizing artificial intelligence (AI) technology for predictive treatment and retreatment
  • Leveraging genomics and imaging research pipeline
  • Partnering with American Academy of Ophthalmology (AAO) and Intelligent Research in Sight (IRIS) to improve disease understanding
  • Promoting health equity and diversity in science, technology, engineering, and math (STEM) through the Health Equity Innovation Fund and the Diverse Future of STEM Fund
  • Investing $90 million toward patient support, STEM education, and health equity programs
Doctors researching in lab in personal protective equipment

Ways we are looking toward the future

  • Utilizing artificial intelligence (AI) technology for predictive treatment and retreatment
  • Leveraging genomics and imaging research pipeline
  • Partnering with American Academy of Ophthalmology (AAO) and Intelligent Research in Sight (IRIS) to improve disease understanding
  • Promoting health equity and diversity in science, technology, engineering, and math (STEM) through the Health Equity Innovation Fund and the Diverse Future of STEM Fund
  • Investing $90 million toward patient support, STEM education, and health equity programs